The Cost-effectiveness of Analogue Insulin Pens in Comparison with Human Insulin Pens for Controlling Type 1, Type 2, and Gestational Diabetes: A Systematic Review Article

2019 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Mohsen Pakdaman ◽  
Rahele Akbari ◽  
Hamid Reza Dehghan ◽  
Reza Valagohar ◽  
Parastoo Rostami ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cost Effectiveness ◽  
Gestational Diabetes ◽  
Human Insulin ◽  
Review Article ◽  
Analogue Insulin ◽  
Insulin Pens ◽  
The Cost

Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus

2016 ◽  
Vol 35 (2) ◽  
pp. 141-162 ◽  
Author(s):  
Asrul Akmal Shafie ◽  
Chin Hui Ng ◽  
Yui Ping Tan ◽  
Nathorn Chaiyakunapruk
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Insulin Analogues ◽  
The Cost

scholarly journals Systematic Review on the Cost-Effectiveness of Therapeutic Education to Prevent the Development and Progression of Type 2 Diabetes

2013 ◽  
Vol 16 (7) ◽  
pp. A452 ◽  
Author(s):  
I. Odnoletkova ◽  
G. Goderis ◽  
L. Pil ◽  
F. Nobels ◽  
B. Aertgeerts ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
Therapeutic Education ◽  
The Cost

scholarly journals Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria

2019 ◽  
Author(s):  
Monika Russel-Szymczyk ◽  
Vasil Valov ◽  
Alexandra Savova ◽  
Manoela Manova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Insulin Glargine ◽  
Cost Effective ◽  
Insulin Degludec ◽  
The Cost

Abstract Background This study investigates the cost-effectiveness of insulin degludec (degludec) versus biosimilar insulin glargine U100 (glargine U100) in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in Bulgaria.Methods A simple, short-term model was used to compare the treatment costs and outcomes associated with hypoglycaemic events with degludec versus glargine U100 in patients with T1DM and T2DM from the perspective of the Bulgarian National Health Insurance Fund. Cost-effectiveness was analysed over a 1-year time horizon using data from clinical trials. The outcome measure was the incremental cost-effectiveness ratio (ICER).Results Degludec was highly cost-effective versus glargine U100 in people with T1DM and T2DM in Bulgaria. The ICERs were estimated to be 4,493.68 BGN/quality-adjusted life year (QALY) in T1DM, 399.11 BGN/QALY in T2DM on basal oral therapy (T2DM BOT ) and 7,365.22 BGN/QALY in T2DM on basal bolus therapy (T2DM B/B ), which all fall below the cost-effectiveness threshold of 39,619 BGN in Bulgaria. Insulin costs were higher with degludec in all three patient groups, however these were partially offset by savings from a reduction in hypoglycaemic events with degludec versus glargine U100. Sensitivity analysis demonstrated that the results were robust and largely insensitive to variations in input parameters. At a willingness-to-pay threshold of 39,619 BGN/QALY, the probability of degludec being cost-effective versus glargine U100 was 60.0% in T1DM, 99.4% in T2DM BOT and 91.3% in T2DM B/B .Conclusion Degludec is a cost-effective alternative to biosimilar glargine U100 for patients with T1DM and T2DM in Bulgaria. Degludec could be of particular benefit to those patients suffering recurrent hypoglycaemia and those who require additional flexibility in the dosing of insulin.

scholarly journals Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Monika Russel-Szymczyk ◽  
Vasil Valov ◽  
Alexandra Savova ◽  
Manoela Manova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Insulin Glargine ◽  
Cost Effective ◽  
Insulin Degludec ◽  
The Cost

Abstract Background This analysis evaluates the cost-effectiveness of insulin degludec (degludec) versus biosimilar insulin glargine U100 (glargine U100) in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in Bulgaria. Methods A simple, short-term model was used to compare the treatment costs and outcomes associated with hypoglycaemic events with degludec versus glargine U100 in patients with T1DM and T2DM from the perspective of the Bulgarian National Health Insurance Fund. Cost-effectiveness was analysed over a 1-year time horizon using data from clinical trials. The incremental cost-effectiveness ratio (ICER) was the main outcome measure. Results In Bulgaria, degludec was highly cost-effective versus glargine U100 in people with T1DM and T2DM. The ICERs were estimated to be 4493.68 BGN/quality-adjusted life year (QALY) in T1DM, 399.11 BGN/QALY in T2DM on basal oral therapy (T2DMBOT) and 7365.22 BGN/QALY in T2DM on basal bolus therapy (T2DMB/B), which are below the cost-effectiveness threshold of 39,619 BGN in Bulgaria. Degludec was associated with higher insulin costs in all three patient groups; however, savings from a reduction in hypoglycaemic events with degludec versus glargine U100 partially offset these costs. Sensitivity analysis demonstrated that the results were robust and largely insensitive to variations in input parameters. At a willingness-to-pay threshold of 39,619 BGN/QALY, the probability of degludec being cost-effective versus glargine U100 was 60.0% in T1DM, 99.4% in T2DMBOT and 91.3% in T2DMB/B. Conclusion Degludec is a cost-effective alternative to biosimilar glargine U100 for patients with T1DM and T2DM in Bulgaria. Degludec could be of particular benefit to those patients suffering recurrent hypoglycaemia and those who require additional flexibility in the dosing of insulin.

Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes

2010 ◽  
Vol 26 (6) ◽  
pp. 1399-1412 ◽  
Author(s):  
William J. Valentine ◽  
Richard F. Pollock ◽  
Juliette Plun-Favreau ◽  
Jeremy White
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
Insulin Aspart ◽  
Biphasic Insulin Aspart ◽  
Biphasic Insulin ◽  
Biphasic Insulin Aspart 30 ◽  
The Cost

scholarly journals Clinical efficacy and safety of insulin aspart compared with regular human insulin in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis

2015 ◽  
Vol 125 (3) ◽  
pp. 141-151
Author(s):  
Piotr Wojciechowski ◽  
Patrycja Niemczyk-Szechowska ◽  
Elżbieta Olewińska ◽  
Patrycja Jaros ◽  
Barbara Mierzejewska ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Human Insulin ◽  
Clinical Efficacy ◽  
Insulin Aspart ◽  
Meta Analysis ◽  
Regular Human Insulin ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document